Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIDIAN: Conversion from calcineurin inhibitor to everolimus in de novo recipients of expanded criteria donor kidneys
2009-018174-54Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in kidney allograft rejection and chronic kidney disease (CKD) (2 arms), sponsored by Novartis. Primary endpoint: Renal function at 12 months post-transplantation. Started Mar 2010; status: terminated.
02
Drugs
everolimus
03
Conditions
kidney allograft rejectionchronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-018174-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018174-54.